{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:59:29Z","timestamp":1780714769210,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12325-021-02016-x","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T02:02:22Z","timestamp":1641175342000},"page":"1055-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Kurt","family":"de Vlam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien Nzeusseu","family":"Toukap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jo\u00eblle","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vanhoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Remans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe","family":"Van den Berghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Di Romana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Lories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"2016_CR1","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis. 2006:1\u201310. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis_en.pdf. Accessed Aug 2021."},{"issue":"Suppl 2","key":"2016_CR2","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2016_CR3","doi-asserted-by":"publisher","first-page":"176298","DOI":"10.1155\/2012\/176298","volume":"2012","author":"P Lloyd","year":"2012","unstructured":"Lloyd P, Ryan C, Menter A. Psoriatic arthritis: an update. Arthritis. 2012;2012:176298.","journal-title":"Arthritis"},{"issue":"4","key":"2016_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin N Am"},{"issue":"5","key":"2016_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405\u201317.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"2016_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.rdc.2015.07.006","volume":"41","author":"JL Barnas","year":"2015","unstructured":"Barnas JL, Ritchlin CT. Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):643\u201363.","journal-title":"Rheum Dis Clin N Am"},{"issue":"10136","key":"2016_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"3","key":"2016_CR8","first-page":"191","volume":"68","author":"PJ Mease","year":"2010","unstructured":"Mease PJ. Psoriatic arthritis\u2014update on pathophysiology, assessment, and management. Bull NYU Hosp Jt Dis. 2010;68(3):191\u20138.","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"3","key":"2016_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40744-019-0159-1","volume":"6","author":"J Belasco","year":"2019","unstructured":"Belasco J, Wei N. Psoriatic arthritis: what is happening at the joint? Rheumatol Ther. 2019;6(3):305\u201315.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"2016_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","volume":"41","author":"DD Gladman","year":"1998","unstructured":"Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41(6):1103\u201310.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"2016_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.12163","volume":"27","author":"C Horreau","year":"2013","unstructured":"Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12\u201329.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2016_CR12","doi-asserted-by":"publisher","first-page":"13030\/qt36n2k4j","DOI":"10.5070\/D3232033960","volume":"23","author":"BC Martin","year":"2017","unstructured":"Martin BC, Thomas LW, Dann FJ. Apremilast for the treatment of psoriatic arthritis. Dermatol Online J. 2017;23(2):13030\/qt36n2k4jw.","journal-title":"Dermatol Online J"},{"issue":"1","key":"2016_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-014-0005-4","volume":"1","author":"PJ Mease","year":"2014","unstructured":"Mease PJ. Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther. 2014;1(1):1\u201320.","journal-title":"Rheumatol Ther"},{"issue":"7","key":"2016_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-014-0218-4","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs. 2014;74(7):825\u201337.","journal-title":"Drugs"},{"issue":"5","key":"2016_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1759720X10381432","volume":"2","author":"G Schett","year":"2010","unstructured":"Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2(5):271\u20138.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2016_CR16","unstructured":"European Medicines Agency. Otezla: Summary of Product Characteristics. 2019:1\u201341. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf."},{"issue":"5","key":"2016_CR17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2016_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","volume":"12","author":"L Gossec","year":"2016","unstructured":"Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12(12):743\u201350.","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"2016_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/annrheumdis-2021-eular.4091","volume":"80","author":"LC Coates","year":"2021","unstructured":"Coates LC, Soriano E, Corp N, et al. OP0229 The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis. 2021;80(Suppl 1):139\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2016_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","volume":"42","author":"AM Orbai","year":"2016","unstructured":"Orbai AM, Ogdie A. Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin N Am. 2016;42(2):265\u201383.","journal-title":"Rheum Dis Clin N Am"},{"key":"2016_CR21","unstructured":"The reimbursement criteria for Otezla in psoriasis in Belgium. https:\/\/ondpanon.riziv.fgov.be\/SSPWebApplicationPublic\/fr\/Public\/ProductSearch. Accessed Aug 2021."},{"key":"2016_CR22","first-page":"839425","volume":"2012","author":"PC Wong","year":"2012","unstructured":"Wong PC, Leung YY, Li EK, Tam LS. Measuring disease activity in psoriatic arthritis. Int J Rheumatol. 2012;2012:839425.","journal-title":"Int J Rheumatol"},{"issue":"6","key":"2016_CR23","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2016_CR24","doi-asserted-by":"publisher","first-page":"e106749","DOI":"10.1371\/journal.pone.0106749","volume":"9","author":"X Janssens","year":"2014","unstructured":"Janssens X, Decuman S, De Keyser F, Belgian Rheumatoid Arthritis Disability Assessment Study Group. Assessment of activity limitations with the health assessment questionnaire predicts the need for support measures in patients with rheumatoid arthritis: a multicenter observational study. PLoS ONE. 2014;9(9):e106749.","journal-title":"PLoS ONE"},{"issue":"Suppl 11","key":"2016_CR25","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S64-85.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"2016_CR26","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724\u201334.","journal-title":"J Rheumatol"},{"issue":"6","key":"2016_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2016_CR28","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","volume":"57","author":"AF Wells","year":"2018","unstructured":"Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford). 2018;57(7):1253\u201363.","journal-title":"Rheumatology (Oxford)"},{"key":"2016_CR29","unstructured":"Wollenhaupt J, Bach C, Roemmler-Zehrer J. Effectiveness and safety of apremilast in biologic-naive versus biologic-experienced patients with psoriatic arthritis in real-world clinical practice settings in Germany: Interim analysis of an ongoing, multicenter, prospective, non-interventional study [abstract]. Arthritis Rheumatol. 2020;72(suppl 10). https:\/\/www.acrabstracts.org\/abstract\/effectiveness-and-safety-of-apremilast-in-biologic-naive-versus-biologic-experienced-patients-with-psoriatic-arthritis-in-real-world-clinical-practice-settings-in-germany-interim-analysis-of-an-ongoi\/. Accessed 5 Aug 2021."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-02016-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T05:28:37Z","timestamp":1700026117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-02016-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-02016-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}